These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, López-Hoyos M, Arias M. Transplantation; 2006 Aug 27; 82(4):550-7. PubMed ID: 16926600 [Abstract] [Full Text] [Related]
23. Impact of immunosuppressive drugs on circulating Tfh cells in kidney transplant recipients: A pilot study. Li YM, Li Y, Shi YY, Yan L, Wu XJ, Tang JT, Bai YJ, Wang LL. Transpl Immunol; 2018 Feb 27; 46():1-7. PubMed ID: 28974433 [Abstract] [Full Text] [Related]
24. Outcomes of sirolimus regimens in 65-year-old and older kidney transplant recipients: a registry-based observational study. Santos AH, Chen C, Alquadan K, Wen X. Int Urol Nephrol; 2019 Nov 27; 51(11):2063-2072. PubMed ID: 31385180 [Abstract] [Full Text] [Related]
28. Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients. Gong N, Chen Z, Wang J, Fang A, Li Y, Xiang Y, Ming C, Zhang W. Cell Immunol; 2015 Oct 27; 297(2):87-93. PubMed ID: 26205091 [Abstract] [Full Text] [Related]
30. Frequency of CD39+, LAG3+, and CTLA4+ Regulatory T Cells in Two Different Immunosuppressive Protocols in Renal Allograft Recipients (Sirolimus vs Mycophenolate mofetil): A Cohort Report. Mollaei-Kandelous Y, Ahmadpoor P, Nafar M, Khatami MR, Farashi Bonab S, Tajik N, Shekarabi M, Amirzargar A. Iran J Immunol; 2022 Sep 27; 19(3):219-231. PubMed ID: 36190377 [Abstract] [Full Text] [Related]
32. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Levitsky J, Gallon L, Miller J, Tambur AR, Leventhal J, Flaa C, Huang X, Sarraj B, Wang E, Mathew JM. Transplantation; 2011 Jan 27; 91(2):199-206. PubMed ID: 21239962 [Abstract] [Full Text] [Related]
35. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L. Transplantation; 2003 Jun 27; 75(12):1934-9. PubMed ID: 12829890 [Abstract] [Full Text] [Related]
38. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q. Transplant Proc; 2008 Jun 27; 40(5):1541-4. PubMed ID: 18589147 [Abstract] [Full Text] [Related]
39. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED. Transplantation; 2006 Aug 15; 82(3):368-74. PubMed ID: 16906035 [Abstract] [Full Text] [Related]
40. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS. Liver Transpl; 2001 Aug 15; 7(8):701-8. PubMed ID: 11510015 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]